



THOMSON MEDICAL GROUP LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

**S\$175,000,000 4.05% NOTES DUE 2025 TO BE ISSUED PURSUANT TO THE S\$500,000,000
MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THOMSON MEDICAL GROUP LIMITED**

The Board of Directors of Thomson Medical Group Limited (the "**Company**") wishes to announce that it has launched and priced S\$175,000,000 in aggregate principal amount of 4.05% notes due 2025 (the "**Series 002 Notes**"). The Series 002 Notes will be issued by the Company, as issuer, pursuant to the S\$500,000,000 Multicurrency Debt Issuance Programme established by the Company on 28 June 2019 (the "**Programme**"). DBS Bank Ltd., Maybank Kim Eng Securities Pte. Ltd. and Standard Chartered Bank (Singapore) Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Series 002 Notes.

The principal terms of the Series 002 Notes are as follows:

Issue Size: **S\$175,000,000**

Issue Price: **100.00% of the principal amount of the Series 002 Notes**

Denomination: **S\$250,000**

Interest: **4.05% per annum payable semi-annually in arrear**

Maturity Date: **5 years from the date of issue**

Interest Reserve: The Series 002 Notes will have the benefit of security over an interest service reserve account in which the Company will maintain an amount equivalent to one interest payment on the Series 002 Notes at all times.

The Series 002 Notes are expected to be issued on 28 January 2020 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited ("SGX-ST**") on the market day after such issue.**

The Series 002 Notes will constitute direct, unconditional and unsubordinated obligations of the Company and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Company. The Series 002 Notes will be secured by a charge over an interest service reserve account as mentioned above.

The Series 002 Notes are offered by the Company in Singapore pursuant to the exemptions invoked under Sections 274 and/or 275 of the Securities and Futures Act, Chapter 289 of Singapore.

The net proceeds arising from the issue of the Series 002 Notes under the Programme (after deducting issue expenses) will be used for the refinancing of certain existing loan facilities.

Application will be made to the SGX-ST for the listing and quotation of the Series 002 Notes on the SGX-ST. Such permission will be granted when the Series 002 Notes have been admitted to the Official

List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 002 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Company, its subsidiaries, its associated companies (if any), the Programme or the Series 002 Notes.

By Order of the Board

Wilson Sam

Executive Director and Group Chief Financial Officer

20 January 2020